Who are Intravenous magnesium sulfate infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Magnesium sulfate 24 hours, Magnesium sulfate administration, Balance Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-magnesium-sulfate-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous magnesium sulfate infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous magnesium sulfate infusion (Intravenous magnesium sulfate infusion) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte/mineral supplement; anticonvulsant; vasodilator. Area: Neurology; Obstetrics; Cardiovascular.

phase 3 Electrolyte/mineral supplement; anticonvulsant; vasodilator NMDA receptor; L-type calcium channel Neurology; Obstetrics; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous magnesium sulfate infusion (Intravenous magnesium sulfate infusion) — Chinese University of Hong Kong. Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous magnesium sulfate infusion TARGET	Intravenous magnesium sulfate infusion	Chinese University of Hong Kong	phase 3	Electrolyte/mineral supplement; anticonvulsant; vasodilator	NMDA receptor; L-type calcium channel
Magnesium sulfate 24 hours	Magnesium sulfate 24 hours	Instituto Materno Infantil Prof. Fernando Figueira	marketed	NMDA receptor antagonist; tocolytic agent; anticonvulsant	NMDA receptor; L-type calcium channels
Magnesium sulfate administration	Magnesium sulfate administration	University of California, San Francisco	marketed	Electrolyte/mineral supplement; anticonvulsant	NMDA receptor; L-type calcium channel
Balance Tablet	Balance Tablet	General Committee of Teaching Hospitals and Institutes, Egypt	marketed	Electrolyte/mineral supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte/mineral supplement; anticonvulsant; vasodilator class)

Chinese University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous magnesium sulfate infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-magnesium-sulfate-infusion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab